Optimization and in vivo evaluation of innovative theranostic imaging probes using Anticalin and PASylation technologies
(A08)
Subject Area
Nuclear Medicine, Radiotherapy, Radiobiology
Term
from 2013 to 2021
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 68647618
Within the new funding period, Project A8 will focus on the development and preclinical evaluation of novel imaging probes such as Anticalins, Fab fragments and other binding proteins as well as bifunctional fusion proteins for pretargeting radio-immuno therapy and diagnostics. Using state of the art protein design concepts, we will apply innovative methods for protein radiolabeling and plasma half-life optimization. Oncologically relevant targets such as the established cell surface receptors/proteins HER2, CEA, PSMA, ED-B, PD-L1 as well as tumor-specific sugars will be addressed in this project.
DFG Programme
Collaborative Research Centres
Major Instrumentation
Field-flow Fractionation
